NLRP3 and Hepatic fibrosis: Moreover, Ang (1–7), an inhibitor of Ang II, can improve bile duct ligation (BDL)-mediated hepatic fibrosis by inhibiting NOX4-dependent ROS and upregulating NRF2/ARE expression to decrease oxidative stress and NLRP3.